A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Cynthia Sirard, MD
Compass Therapeutics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
34 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Arizona
Phoenix, Arizona, United States
- University of Arizona
Tucson, Arizona, United States
- University of Southern California Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Stanford Medicine Cancer Center
Palo Alto, California, United States
- University of California San Francisco
San Francisco, California, United States
- Rocky Mountain Cancer Centers, Llp
Aurora, Colorado, United States
- University of Florida
Gainesville, Florida, United States
- Mayo Clinic Jacksonville
Jacksonville, Florida, United States
- Adventhealth Orlando
Orlando, Florida, United States
- Northwestern University
Chicago, Illinois, United States
- University of Chicago
Chicago, Illinois, United States
- Ochsner Clinic Foundation
New Orleans, Louisiana, United States
- Johns Hopkins University
Baltimore, Maryland, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Mayo Clinic Rochester
Rochester, Minnesota, United States
- Washington University School of Medicine, Siteman Cancer Center
St Louis, Missouri, United States
- Rutgers Cancer Institute
New Brunswick, New Jersey, United States
- the University of New Mexico
Albuquerque, New Mexico, United States
- Memorial Medical Center
Las Cruces, New Mexico, United States
- Roswell Park
Buffalo, New York, United States
- Columbia University
New York, New York, United States
- Montefiore Medical Center
The Bronx, New York, United States
- Gabrail Cancer Center
Canton, Ohio, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- University of Tennessee Medical Center
Knoxville, Tennessee, United States
- Scri Oncology Partners
Nashville, Tennessee, United States
- Texas Oncology - Austin
Austin, Texas, United States
- Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
- Texas Oncology - Dension
Denison, Texas, United States
- the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
- Texas Oncology - San Antonio
San Antonio, Texas, United States
- Texas Oncology - Northeast Texas
Tyler, Texas, United States
- Virginia Mason Franciscan Health
Seattle, Washington, United States
- Northwest Cancer Specialists, P.C.
Vancouver, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Jan 2023
- Primary completion
- 1 Dec 2026
- Completion
- 1 Dec 2026
- Last update posted
- 7 May 2026
- Registered enrollment
- 168
- Registry id
- NCT05506943
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.